The recent controversy surrounding Galena Biopharma (GALE) has sent the stock plummeting in the face of the upcoming annual report. One of the key points investors are anxious to see is how well Abstral has been marketed and sold. The success or failure of the drug will have significant impacts for the short term success of the stock, and depending on the numbers, I expect there will be a significant amount of money flow into the stock. The company will likely announce the sales report for Abstral during the year-end earnings report, estimated to happen the week of March 10th-14th. In light of this, here's some analysis and figuring on where they were last quarter, and where they could be this quarter.